Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen™; Ghryvelin®), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need, in collaboration with Novo Nordisk.
Aeterna Zentaris is dedicated to the development of therapeutic assets and has taken steps to establish a growing pre-clinical pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease).
We are focused on leveraging our research and clinical development expertise to advance medicines that improve the quality of life of patients with significant unmet medical needs across a range of therapeutic areas.
Establish Aeterna Zentaris as a global leader in the development and commercialization of therapeutic and diagnostic assets that have the potential to enhance the lives of patients in need.
We pledge to act with Integrity — comprising Fairness, Honesty and Perseverance especially when facing difficulties or challenges. In our everyday work, we focus on those values while upholding the highest ethical standards: Teamwork, Transparency, Innovation, and Integrity.